Skip to main content
Top

Breast Cancer Research and Treatment

Issue 1/2009

Content (24 Articles)

Review

Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival

Andrea C. Bafford, Harold J. Burstein, Christina R. Barkley, Barbara L. Smith, Stuart Lipsitz, James D. Iglehart, Eric P. Winer, Mehra Golshan

Review

Role of melatonin in the epigenetic regulation of breast cancer

Ahmet Korkmaz, Emilio J. Sanchez-Barcelo, Dun-Xian Tan, Russel J. Reiter

Preclinical Study

PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity

Jie Gao, Geng Kou, Hao Wang, Huaiwen Chen, Bohua Li, Ying Lu, Dapeng Zhang, Shuhui Wang, Sheng Hou, Weizhu Qian, Jianxin Dai, Jian Zhao, Yanqiang Zhong, Yajun Guo

Preclinical Study

Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives

A-Yong Cao, Juan Huang, Zhen Hu, Wen-Feng Li, Zhong-Liang Ma, Li-Li Tang, Bin Zhang, Feng-Xi Su, Jie Zhou, Gen-Hong Di, Kun-Wei Shen, Jiong Wu, Jin-Song Lu, Jian-Min Luo, Wen-Tao Yuan, Zhen-Zhou Shen, Wei Huang, Zhi-Ming Shao

Preclinical Study

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells

S. Hiscox, N. J. Jordan, C. Smith, M. James, L. Morgan, K. M. Taylor, T. P. Green, R. I. Nicholson

Preclinical Study

A common Greenlandic Inuit BRCA1 RING domain founder mutation

Thomas v. O. Hansen, Bent Ejlertsen, Anders Albrechtsen, Eva Bergsten, Peter Bjerregaard, Torben Hansen, Torben Myrhøj, Peter B. Nielsen, Vera Timmermans-Wielenga, Mette K. Andersen, Lars Jønson, Finn C. Nielsen

Preclinical Study

Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome

Malini Harigopal, Jonas Heymann, Sriparna Ghosh, Valsamo Anagnostou, Robert L. Camp, David L. Rimm

Clinical Trial

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

G. Fountzilas, U. Dafni, M. A. Dimopoulos, A. Koutras, D. Skarlos, P. Papakostas, H. Gogas, D. Bafaloukos, A. Kalogera-Fountzila, E. Samantas, E. Briasoulis, D. Pectasides, N. Maniadakis, F. Matsiakou, G. Aravantinos, C. Papadimitriou, M. Karina, C. Christodoulou, P. Kosmidis, H. P. Kalofonos

Clinical Trial

Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902

Johanna G. H. van Nes, Hein Putter, Jean-Pierre Julien, Michelle Tubiana-Hulin, Marc van de Vijver, Jan Bogaerts, Monika de Vos, Cornelis J. H. van de Velde

Clinical Trial

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

Maura N. Dickler, Melody A. Cobleigh, Kathy D. Miller, Pamela M. Klein, Eric P. Winer

Clinical Trial

The impact of sharing results of a randomized breast cancer clinical trial with study participants

Ann H. Partridge, A. C. Wolff, P. K. Marcom, P. A. Kaufman, L. Zhang, R. Gelman, C. Moore, D. Lake, G. F. Fleming, H. S. Rugo, J. Atkins, E. Sampson, D. Collyar, E. P. Winer

Clinical Trial

Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer

Alessandra Gennari, Michele De Tursi, Consiglia Carella, Enrico Ricevuto, Cinzia Orlandini, Antonio Frassoldati, Pierfranco Conte, Paolo Bruzzi, Stefano Iacobelli

Epidemiology

The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case–control and family analysis

Sharon E. Johnatty, Jonathan Beesley, Xiaoqing Chen, John L. Hopper, Melissa C. Southey, Graham G. Giles, David E. Goldgar, Georgia Chenevix-Trench, Amanda B. Spurdle

Epidemiology

Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics

Lina Mu, Dionyssios Katsaros, Andrew Wiley, Lingeng Lu, Irene A. Rigault de la Longrais, Stephanie Smith, Sapna Khubchandani, Olga Sochirca, Riccardo Arisio, Herbert Yu

Epidemiology

Ethnic differences in the use of regular mammography: the multiethnic cohort

Quannetta T. Edwards, Arthur X. Li, Malcolm C. Pike, Laurence N. Kolonel, Giske Ursin, Brian E. Henderson, Roberta McKean-Cowdin

Epidemiology

Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition

Laura Baglietto, Dallas R. English, John L. Hopper, Robert J. MacInnis, Howard A. Morris, Wayne D. Tilley, Kavitha Krishnan, Graham G. Giles

Epidemiology

Screening caused rising incidence rates of ductal carcinoma in situ of the breast

L. N. van Steenbergen, A. C. Voogd, J. A. Roukema, W. J. Louwman, L. E. M. Duijm, J. W. W. Coebergh, L. V. van de Poll-Franse

Epidemiology

No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study

Timothy R. Rebbeck, Antonis C. Antoniou, Trinidad Caldes Llopis, Heli Nevanlinna, Kristiina Aittomäki, Jacques Simard, Amanda B. Spurdle, Fergus J. Couch, Lutecia H. Mateus Pereira, Mark H. Greene, Irene L. Andrulis, Boris Pasche, Virginia Kaklamani, Ute Hamann, Csilla Szabo, Susan Peock, Margaret Cook, Patricia A. Harrington, Alan Donaldson, Allison M. Male, Carol Anne Gardiner, Helen Gregory, Lucy E. Side, Anne C. Robinson, Louise Emmerson, Ian Ellis, Jean-Philippe Peyrat, Joëlle Fournier, Philippe Vennin, Claude Adenis, Danièle Muller, Jean-Pierre Fricker, Michel Longy, Olga M. Sinilnikova, Dominique Stoppa-Lyonnet, Rita K. Schmutzler, Beatrix Versmold, Christoph Engel, Alfons Meindl, Karin Kast, Dieter Schaefer, Ursula G. Froster, Georgia Chenevix-Trench, Douglas F. Easton

Epidemiology

Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points

Bilal Majed, Thierry Moreau, Bernard Asselain

Brief Report

Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?

S. J. Beyer, R. E. Jimenez, C. L. Shapiro, J. Y. Cho, S. M. Jhiang

Brief Report

Prepubertal physical activity up-regulates estrogen receptor β, BRCA1 and p53 mRNA expression in the rat mammary gland

M. Wang, B. Yu, K. Westerlind, R. Strange, G. Khan, D. Patil, K. Boeneman, L. Hilakivi-Clarke

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine